


CLAIMS

1. A compound of formula (I) or a salt thereof




wherein

R_1 represents a hydrogen atom, a methyl group or an ethyl group

R_2 represents a hydrogen atom or a fluorine atom

R_3 represents a hydrogen atom, a methyl group or an ethyl group.

2. A compound according to claim 1 or a salt thereof wherein R_1 represents a methyl group, R_2 represents a hydrogen atom and R_3 represents a methyl group.
3. A compound according to claim 1 or a salt thereof in which R_1 represents a methyl group, R_2 represents a hydrogen atom and R_3 represents a hydrogen atom.
4. A compound according to claim 1 or a salt thereof wherein R_1 represents a methyl group, R_2 represents a fluorine atom and R_3 represents methyl group.
5. A compound according to claim 1 or a salt thereof in which R_1 represents a hydrogen atom, R_2 represents a hydrogen atom and R_3 represents a hydrogen atom.
6. A compound according to claim 1 or a salt thereof in which R_1 represents an ethyl group, R_2 represents a hydrogen atom and R_3 represents a methyl group.
7. A compound according to claim 1 or a salt thereof in which R_1 represents an ethyl group, R_2 represents a hydrogen atom and R_3 represents an ethyl group.
8. A compound according to claim 1 or a salt thereof in which R_1 represents a hydrogen atom, R_2 represents a hydrogen atom and R_3 represents a methyl group.
9. A compound of formula (I):



wherein

R_1 represents a hydrogen atom, a methyl group or an ethyl group


13. A compound according to claim 1 which is 3-(3-(3,5-Dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt.
14. A compound according to claim 1 which is (*S*)-3-(3-(3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt.
15. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in therapy.
16. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or condition for which an $\alpha_v\beta_6$ receptor antagonist is indicated.
17. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in the treatment of idiopathic pulmonary fibrosis.
18. A method Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of disorders in which antagonism of an $\alpha_v\beta_6$ receptor is beneficial in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.
19. A method Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of disorders in which antagonism of an $\alpha_v\beta_6$ receptor is beneficial in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.
20. A method Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of fibrotic diseases in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.
21. A method Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of fibrotic diseases in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.
22. A method Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a

~~medicament for the treatment of idiopathic pulmonary fibrosis in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~

23. ~~A method Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of idiopathic pulmonary fibrosis in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.~~

24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

25. The use of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition for which an $\alpha_v\beta_6$ receptor antagonist is indicated.
26. A compound of formula (II) or a salt thereof




(II)

- where R_1 represents a hydrogen atom, a methyl group or an ethyl group
- R_2 represents a hydrogen atom or a fluorine atom
- R_3 represents a hydrogen atom, a methyl group or an ethyl group and
- R_4 is a C_1 to C_6 alkyl group
27. A compound as claimed in claim 26 wherein R_4 represents a *tert*-Bu, iso-propyl, an ethyl or a methyl group.
28. A compound as claimed in claim 27 which is methyl 3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoate
29. A compound as claimed in claim 27 which is *tert*-Butyl 3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoate.

CLAIMS

1. A compound of formula (I) or a salt thereof




wherein

R_1 represents a hydrogen atom, a methyl group or an ethyl group

R_2 represents a hydrogen atom or a fluorine atom

R_3 represents a hydrogen atom, a methyl group or an ethyl group.

2. A compound according to claim 1 or a salt thereof wherein R_1 represents a methyl group, R_2 represents a hydrogen atom and R_3 represents a methyl group.
3. A compound according to claim 1 or a salt thereof in which R_1 represents a methyl group, R_2 represents a hydrogen atom and R_3 represents a hydrogen atom.
4. A compound according to claim 1 or a salt thereof wherein R_1 represents a methyl group, R_2 represents a fluorine group and R_3 represents methyl group.
5. A compound according to claim 1 or a salt thereof in which R_1 represents a hydrogen atom, R_2 represents a hydrogen atom and R_3 represents a hydrogen atom.
6. A compound according to claim 1 or a salt thereof in which R_1 represents an ethyl group, R_2 represents a hydrogen atom and R_3 represents a methyl group.
7. A compound according to claim 1 or a salt thereof in which R_1 represents an ethyl group, R_2 represents a hydrogen atom and R_3 represents an ethyl group.
8. A compound according to claim 1 or a salt thereof in which R_1 represents a hydrogen atom, R_2 represents a hydrogen atom and R_3 represents a methyl group.
9. A compound according to claim 1 of formula (I):



wherein

R_1 represents a hydrogen atom, a methyl group or an ethyl group

13. A compound according to claim 1 which is 3-(3-(3,5-Dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt.
14. A compound according to claim 1 which is (*S*)-3-(3-(3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid hydrochloride salt.
15. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in therapy.
16. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or condition for which an $\alpha_v\beta_6$ receptor antagonist is indicated.
17. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for use in the treatment of idiopathic pulmonary fibrosis.
18. Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of fibrotic diseases selected from the group consisting of pulmonary fibrosis, idiopathic pulmonary fibrosis, non-specific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), Hermansky-Pudlak syndrome, progressive massive fibrosis, connective tissue disease-related pulmonary fibrosis, airway fibrosis in asthma and COPD, acute respiratory distress syndrome (ARDS) associated fibrosis, acute lung injury, radiation-induced fibrosis, familial pulmonary fibrosis, pulmonary hypertension, renal fibrosis, diabetic nephropathy, IgA nephropathy, lupus nephritis, focal segmental glomerulosclerosis (FSGS), transplant nephropathy, autoimmune nephropathy, drug-induced nephropathy, hypertension-related nephropathy, nephrogenic systemic fibrosis, liver fibrosis, viral-induced fibrosis, hepatitis C, hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), congenital hepatic fibrosis, primary sclerosing cholangitis, drug-induced hepatitis, hepatic cirrhosis, skin fibrosis, hypertrophic scars, scleroderma, keloids, dermatomyositis, eosinophilic fasciitis, Dupuytren's contracture, Ehlers-Danlos syndrome, Peyronie's disease epidermolysis bullosa dystrophica, oral submucous fibrosis, ocular fibrosis, AMD, diabetic macular oedema, dry eye, glaucoma, cardiac fibrosis, congestive heart failure, endomyocardial fibrosis, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertensive heart disease, cardiac sarcoidosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, Crohn's disease, neurofibromatosis, uterine leiomyomas, uterine fibroids and chronic organ transplant rejection in a human in need thereof.


19. Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of fibrotic diseases selected from the group consisting of pulmonary fibrosis, idiopathic pulmonary fibrosis, non-specific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), Hermansky-Pudlak syndrome, progressive massive fibrosis, connective tissue disease-related pulmonary fibrosis, airway fibrosis in asthma and COPD, acute respiratory distress syndrome (ARDS) associated fibrosis, acute lung injury, radiation-induced fibrosis, familial pulmonary fibrosis, pulmonary hypertension, renal fibrosis, diabetic nephropathy, IgA nephropathy, lupus nephritis, focal segmental glomerulosclerosis (FSGS), transplant nephropathy, autoimmune nephropathy, drug-induced nephropathy, hypertension-related nephropathy, nephrogenic systemic fibrosis, liver fibrosis, viral-induced fibrosis, hepatitis C, hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), congenital hepatic fibrosis, primary sclerosing cholangitis, drug-induced hepatitis, hepatic cirrhosis, skin fibrosis, hypertrophic scars, scleroderma, keloids, dermatomyositis, eosinophilic fasciitis, Dupuytren's contracture, Ehlers-Danlos syndrome, Peyronie's disease, epidermolysis bullosa dystrophica, oral submucous fibrosis, ocular fibrosis, AMD, diabetic macular oedema, dry eye, glaucoma, cardiac fibrosis, congestive heart failure, endomyocardial fibrosis, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertensive heart disease, cardiac sarcoidosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, Crohn's disease, neurofibromatosis, uterine leiomyomas, uterine fibroids and chronic organ transplant rejection in a human in need thereof.

20. Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of idiopathic pulmonary fibrosis in a human in need thereof.

21. Use of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prophylaxis of idiopathic pulmonary fibrosis in a human in need thereof.

22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

23. A compound of formula (II) or a salt thereof



(II)

where R₁ represents a hydrogen atom, a methyl group or a ethyl group

R₂ represents a hydrogen atom or a fluorine atom

R₃ represents a hydrogen atom, a methyl group or an ethyl group and

R₄ is a C₁ to C₆ alkyl group

24. A compound as claimed in claim 23 wherein R₄ represents a *tert*-Bu, iso-propyl, an ethyl or a methyl group.

25. A compound as claimed in claim 24 which is methyl 3-(3-(3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoate.

26. A compound as claimed in claim 24 which is *tert*-Butyl 3-(3-(3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl)-4-((*R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoate.